Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DOXEPIN HCL

All products: general benefit

Other products in the same Health Canada class (N06AA) — coverage varies; not interchangeable

  • Amitriptyline (Elavil): general benefit
  • Clomipramine (Anafranil Tab): general benefit
  • Desipramine (Pertofrane): general benefit, Not a benefit
  • Imipramine (Tofranil): general benefit, Not a benefit
  • Nortriptyline (Aventyl): general benefit
  • Trimipramine (Surmontil): general benefit, Not a benefit

17 more in the class list below

Sinequan · DIN 00024325 · 10mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sinequan · DIN 00024325 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2017-12-29 · brand SINEQUAN · ATC N06AA12 DOXEPIN · form Capsule · route Oral · ingredients DOXEPIN (DOXEPIN HYDROCHLORIDE) 10 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=944 · Verify on the e-Formulary ↗ (DIN 00024325)

Source record
DIN 00024325: Sinequan Raw flags: sec3=Y Item: 281604010; group id 458; item number 1143; lccId None; manufacturer id AAP Source form: Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.4075; ministry $0.1019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00024325 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=944
Interchangeable products
Apo-Doxepin · DIN 02049996 · $0.1019 Jamp Doxepin · DIN 02559250 · $0.1019 Mar-Doxepin · DIN 02559080 · $0.1019
Shortage status: resolved shortage (ended 2025-01-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00024325
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

NORTRIPTYLINE

· 2 products · General benefit · strengths: 10mg, 25mg · Cap

TRIMIPRAMINE

· 10 products · Listed, not a benefit (5), General benefit (5) · strengths: 75mg, 12.5mg, 25mg, 50mg, 100mg · Cap, Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS The antidepressant and anxiolytic properties of SINEQUAN (doxepin HCl) have been found to be of value in the drug treatment of: 1. Psychoneurotic patients with anxiety and/or depressive reactions; Anxiety neurosis associated with somatic disorders; Alcoholic patients with anxiety and/or depression. 2. Psychotic depression, including manic-depressive illness (depressed type) and involutional melancholia. CLINICAL USE Controlled clinical trials have confirmed that SINEQUAN (doxepin HCl) is an effective psychotropic agent with antidepressant and anxiolytic properties. SINEQUAN has been found useful in alleviating manifest anxiety in neurotic patients including those with somatic disorders. It has also been found useful in patients with neurotic depression, including those with mixed anxiety and depression. Patients with endogenous or psychotic depression, including manic-depressive illness (depressed type), and involutional melancholia, have also been reported to respond favorably to SINEQUAN. As adjunctive medication, … https://pdf.hres.ca/dpd_pm/00047238.PDF PM date: August 31, 2018 Source product: SINEQUAN; DIN 00024325; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.